Literature DB >> 18987777

Pregnancy and rheumatic disease: "by the book" or "by the doc".

Stephanie O Keeling1, Anna E Oswald.   

Abstract

Pregnancy is an important condition that can affect and be affected by rheumatic disease. Overall, pregnancy is viewed as a Th2-predominant state, but several Th1-related cytokines are vital to early pregnancy. In rheumatoid arthritis for example, the majority of women improve by the beginning of the second trimester, but the majority (90%) will flare in the first 3 to 4 months postpartum. In contrast, systemic lupus erythematosus has an unpredictable course in pregnancy, leaving most rheumatologists to recommend a disease-quiescent state prior to conception. Other diseases such as scleroderma are less clear because the disease less commonly presents in the childbearing period. Many immunosuppressive medications for the rheumatic diseases are contraindicated in pregnancy because of their mechanisms of action leaving only a select few "safe" medications. Significant heterogeneity between the Food and Drug Administration (FDA) category for a medication and what a rheumatologist does in clinic leads to confusion on how a patient should be treated for active rheumatic disease both peripartum and postpartum, particularly if the patient is breastfeeding. We review the general state of pregnancy and how it is affected by prototypical rheumatic diseases including rheumatoid arthritis and systemic lupus erythematosus. In addition, we present the most commonly used disease-modifying antirheumatic drugs and immunosuppressants and explain the difference between the FDA category and clinical practice among rheumatologists. Finally, we provide some general recommendations on how to manage a rheumatic disease during pregnancy including: (a) preconception planning to ensure no teratogenic medications on board, (b) early disclosure of pregnancy to all caregivers including the rheumatologist, family physician, obstetrician, and maternal-fetal medicine specialist, and (c) planning of safe medication use for acute flare-ups and disease suppression peripartum and postpartum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987777     DOI: 10.1007/s10067-008-1031-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  51 in total

1.  Report from the national transplantation pregnancy registry (NTPR): outcomes of pregnancy after transplantation.

Authors:  V T Armenti; J S Radomski; M J Moritz; W J Gaughan; L Z Philips; C H McGrory; L A Coscia
Journal:  Clin Transpl       Date:  2001

Review 2.  Treating rheumatic diseases in pregnancy: dos and don'ts.

Authors:  M D Lockshin
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

3.  Levels of dimethylarginines and cytokines in mild and severe preeclampsia.

Authors:  J Ellis; U B Wennerholm; A Bengtsson; H Lilja; A Pettersson; B Sultan; M Wennergren; H Hagberg
Journal:  Acta Obstet Gynecol Scand       Date:  2001-07       Impact factor: 3.636

4.  Pregnancy does not cause systemic lupus erythematosus to worsen.

Authors:  M D Lockshin
Journal:  Arthritis Rheum       Date:  1989-06

5.  Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertories, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line.

Authors:  Kotaro Fukushima; Shingo Miyamoto; Kiyomi Tsukimori; Hiroaki Kobayashi; Hiroyuki Seki; Satoru Takeda; Egashira Kensuke; Kishio Ohtani; Masabumi Shibuya; Hitoo Nakano
Journal:  Biol Reprod       Date:  2005-03-23       Impact factor: 4.285

6.  Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study.

Authors:  C J Hardy; B P Palmer; S J Morton; K R Muir; R J Powell
Journal:  Rheumatology (Oxford)       Date:  1999-06       Impact factor: 7.580

7.  Safety of rituximab therapy during the first trimester of pregnancy: a case history.

Authors:  Eva Kimby; Asgerdur Sverrisdottir; Göran Elinder
Journal:  Eur J Haematol       Date:  2004-04       Impact factor: 2.997

8.  Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid.

Authors:  M J Kupferminc; A M Peaceman; D Aderka; D Wallach; M R Peyser; J B Lessing; M L Socol
Journal:  Am J Obstet Gynecol       Date:  1995-09       Impact factor: 8.661

Review 9.  New insights into sexual functioning and fertility in rheumatic diseases.

Authors:  Monika Østensen
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-04       Impact factor: 4.098

Review 10.  TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm.

Authors:  Gérard Chaouat; Natalie Ledée-Bataille; Sylvie Dubanchet; Sandrine Zourbas; Olivier Sandra; Jacques Martal
Journal:  Int Arch Allergy Immunol       Date:  2004-05-17       Impact factor: 2.749

View more
  11 in total

Review 1.  The role of sex in uveitis and ocular inflammation.

Authors:  Ian Y L Yeung; Nicholas A Popp; Chi-Chao Chan
Journal:  Int Ophthalmol Clin       Date:  2015

Review 2.  The treatment of rheumatoid arthritis during pregnancy.

Authors:  Rosamund Partlett; Euthalia Roussou
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

Review 3.  Management of obstetric antiphospholipid syndrome.

Authors:  Guilherme Ribeiro Ramires de Jesus; Flavia Cunha dos Santos; Camila Souto Oliveira; Wallace Mendes-Silva; Nilson Ramires de Jesus; Roger Abramino Levy
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

4.  Association between pregnancy and acute appendicitis in South Korea: a population-based, cross-sectional study.

Authors:  Jin-Sung Yuk; Yong Jin Kim; Jun-Young Hur; Jung-Ho Shin
Journal:  J Korean Surg Soc       Date:  2013-07-25

Review 5.  Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review.

Authors:  Abir Mokbel; Daeria O Lawson; Forough Farrokhyar
Journal:  Clin Rheumatol       Date:  2021-01-19       Impact factor: 2.980

6.  Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.

Authors:  Arwa Z Alromaih; Abdullah I Almater; Abdulrahman F Albloushi; Norah F Alkheraiji; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2022-08-09       Impact factor: 2.029

7.  Dermatomyositis onset in the puerperium period.

Authors:  Sofia Mateus; Mariana Malheiro; Miguel Perneta Santos; Rui Costa
Journal:  BMJ Case Rep       Date:  2015-09-11

Review 8.  Managing pregnancy in inflammatory rheumatological diseases.

Authors:  Varsha Jain; Caroline Gordon
Journal:  Arthritis Res Ther       Date:  2011-02-25       Impact factor: 5.156

Review 9.  Uveitis and gender: the course of uveitis in pregnancy.

Authors:  Nathalie P Y Chiam; Lyndell L P Lim
Journal:  J Ophthalmol       Date:  2014-01-09       Impact factor: 1.909

10.  Association of MICA with rheumatoid arthritis independent of known HLA-DRB1 risk alleles in a family-based and a case control study.

Authors:  Holger Kirsten; Elisabeth Petit-Teixeira; Markus Scholz; Dirk Hasenclever; Helene Hantmann; Dirk Heider; Ulf Wagner; Ulrich Sack; Vitor Hugo Teixeira; Bernard Prum; Jana Burkhardt; Céline Pierlot; Frank Emmrich; François Cornelis; Peter Ahnert
Journal:  Arthritis Res Ther       Date:  2009-05-01       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.